Targeting PI3K/Akt signaling in prostate cancer therapy

M Hashemi, A Taheriazam, P Daneii… - Journal of Cell …, 2023 - Springer
Urological cancers have obtained much attention in recent years due to their mortality and
morbidity. The most common and malignant tumor of urological cancers is prostate cancer …

Non-coding RNAs and macrophage interaction in tumor progression

M Entezari, M Sadrkhanloo, M Rashidi, SE Asnaf… - Critical reviews in …, 2022 - Elsevier
The macrophages are abundantly found in TME and their M2 polarization is in favor of tumor
malignancy. On the other hand, non-coding RNAs (ncRNAs) can modulate macrophage …

[HTML][HTML] Factors influencing degradation kinetics of mRNAs and half-lives of microRNAs, circRNAs, lncRNAs in blood in vitro using quantitative PCR

C Wang, H Liu - Scientific Reports, 2022 - nature.com
RNAs are rapidly degraded in samples and during collection, processing and testing. In this
study, we used the same method to explore the half-lives of different RNAs and the …

[HTML][HTML] From omics to multi-omics approaches for in-depth analysis of the molecular mechanisms of prostate cancer

E Nevedomskaya, B Haendler - International Journal of Molecular …, 2022 - mdpi.com
Cancer arises following alterations at different cellular levels, including genetic and
epigenetic modifications, transcription and translation dysregulation, as well as metabolic …

[HTML][HTML] circPHF16 suppresses prostate cancer metastasis via modulating miR-581/RNF128/Wnt/β-catenin pathway

L Ding, Y Lin, X Chen, R Wang, H Lu, H Wang, W Luo… - Cellular …, 2023 - Elsevier
Circular RNAs (circRNAs) have been recognized as important regulators in tumorigenesis.
However, the specific role of circRNAs in prostate cancer is still largely unknown. Here, we …

[HTML][HTML] Current therapeutic modalities and chemopreventive role of natural products in liver cancer: Progress and promise

AK Singh, SV Singh, R Kumar, S Kumar… - World journal of …, 2023 - ncbi.nlm.nih.gov
Liver cancer is a severe concern for public health officials since the clinical cases are
increasing each year, with an estimated 5-year survival rate of 30%–35% after diagnosis …

[HTML][HTML] Androgen-Responsive Oncogenic lncRNA RP11-1023L17. 1 Enhances c-Myc protein stability in prostate cancer

W Huang, Q Chen, Y Lu, Z Kong, X Wan… - International Journal of …, 2022 - mdpi.com
Long noncoding RNAs (lncRNAs) have been found as novel participants in the
pathophysiology of prostate cancer (PCa), which is predominantly regulated by androgen …

[HTML][HTML] An emerging link between lncRNAs and cancer sex dimorphism

I Naciri, MD Andrade-Ludena, Y Yang, M Kong, S Sun - Human Genetics, 2023 - Springer
The prevalence and progression of cancer differ in males and females, and thus, sexual
dimorphism in tumor development directly impacts clinical research and medicine. Long non …

Androgen‐repressed lncRNA LINC01126 drives castration‐resistant prostate cancer by regulating the switch between O‐GlcNAcylation and phosphorylation of …

Y Cai, M Chen, Y Gong, G Tang, Z Shu… - Clinical and …, 2024 - Wiley Online Library
Abstract Background Prostate cancer (PCa) initially shows satisfactory response to therapies
targeting the androgen receptor (AR). However, progression to a castration‐resistant stage …

Non-coding RNAs in gynecologic cancer

A Solati, S Thvimi, SH Khatami, Z Shabaninejad… - Clinica Chimica …, 2023 - Elsevier
The term “gynecologic cancer” pertains to neoplasms impacting the reproductive tissues and
organs of women encompassing the endometrium, vagina, cervix, uterus, vulva, and …